Filtered By:
Source: International Journal of Cardiology
Drug: Aspirin
This page shows you your search results in order of date.
Order by Relevance | Date
Total 22 results found since Jan 2013.
REACHing conclusions on the external applicability of the THEMIS into clinical practice
The THEMIS Study (Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients) was a phase 3 randomized, double-blinded, placebo-controlled trial from 2014 to 2016. Patients with angiographically proven coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM), but no prior history of myocardial infarction (MI) or stroke, were randomized 1:1 to either ticagrelor or placebo in addition to low-dose aspirin for a median follow-up of 39.9 months. The randomized population (n = 19,220) had a median age of 66years, 31.4% were women, and there was a high prevalence of concomitant hypertension, dyslipidemi...
Source: International Journal of Cardiology - December 31, 2022 Category: Cardiology Authors: Rahul Gupta, Adriana C. Mares Tags: Editorial Source Type: research
Antithrombotic therapy after acute coronary syndromes in patients with atrial fibrillation: Shouldn't we pay more attention to the risk of ischemic and thromboembolic events?
The management of antithrombotic therapy in patients with atrial fibrillation (AF) presenting an acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI) is particularly complex. Oral anticoagulation (OAC) is superior to single or dual antiplatelet therapy (DAPT) for the prevention of thromboembolic complications (stroke and systemic embolism) due to AF, whereas DAPT with low-dose aspirin and a P2Y12 inhibitor is the recommended antithrombotic treatment to prevent ischemic events (myocardial infarction and stent thrombosis) in patients with ACS or undergoing PCI.
Source: International Journal of Cardiology - November 29, 2018 Category: Cardiology Authors: Jos é Luis Ferreiro, Joan Antoni Gómez-Hospital Tags: Editorial Source Type: research
Finding the right balance
Patients with an indication for oral anticoagulation (OAC) that receive antiplatelet therapy after percutaneous coronary intervention (PCI) are challenging for the treating physician. It is of importance to balance their antithrombotic treatment to protect them from ischemic events, such as stent thrombosis as well as ischemic stroke without exposing them to an excess in bleeding. The current guidelines recommend a so-called triple therapy consisting of aspirin, clopidogrel and OAC for 1 –6 months after PCI depending on the patient's ischemic risk [1].
Source: International Journal of Cardiology - September 27, 2018 Category: Cardiology Authors: Alexander Goedel, Nikolaus Sarafoff Tags: Editorial Source Type: research
Oral anticoagulation alone for concomitant stable coronary artery disease and atrial fibrillation: A definitive strategy?
Thrombus formation, albeit with partially different mechanisms, is the common denominator of adverse ischemic events in both coronary artery disease (CAD) and atrial fibrillation (AF) [1]. Accordingly, long-term oral antiplatelet therapy with aspirin, and oral anticoagulation (OAC) with either warfarin or a direct oral anticoagulant (DOAC), including dabigatran, rivaroxaban, apixaban, and edoxaban, have long been established as the standard treatments for the prevention of (recurrent) cardiac ischemic events and stroke, respectively [2].
Source: International Journal of Cardiology - May 16, 2018 Category: Cardiology Authors: Andrea Rubboli Source Type: research
Analgesic medication with dipyrone in patients with coronary artery disease: relation to MACCE
In this study, we investigated the incidence of death, myocardial infarction (MI) or stroke in CAD patients with aspirin and dipyrone comedication as compared to aspirin-alone.
Source: International Journal of Cardiology - February 25, 2017 Category: Cardiology Authors: Alina Achilles, Annemarie Mohring, Lisa Dannenberg, Kerstin Piayda, Bodo Levkau, Thomas Hohlfeld, Tobias Zeus, Malte Kelm, Amin Polzin Source Type: research
Cost-effectiveness Modelling of Novel Oral Anticoagulants Incorporating Real-world Elderly Patients with Atrial Fibrillation
Novel oral anticoagulants (NOACs) expand the treatment options for patients with atrial fibrillation (AF). Their benefits need to be weighed against the risk-benefit ratio in real-world elderly patients, prompting this cost-effectiveness study of NOACs (apixaban, dabigatran, edoxaban and rivaroxaban), warfarin and aspirin for stroke prevention in AF.
Source: International Journal of Cardiology - June 22, 2016 Category: Cardiology Authors: Ying Jiao Zhao, Liang Lin, Hui Jun Zhou, Keng Teng Tan, Aik Phon Chew, Chee Guan Foo, Chia Theng Daniel Oh, Boon Peng Lim, Wee Shiong Lim Source Type: research
Percutaneous left atrial appendage occlusion: Device thrombosis in clopidogrel non-responders
Percutaneous left atrial appendage closure (LAAC) has been recently proposed as a safe and effective strategy to reduce the embolic stroke risk in patients with atrial fibrillation that are not amenable to long lasting oral anticoagulation [1]. After LACC, a temporary double anti-platelets regimen with aspirin and clopidogrel is suggested to prevent closure device thrombosis and enhance its endothelization [2]. Although clopidogrel resistance has been associated with recurrent cardiac events after percutaneous coronary intervention [3], no reports exist concerning the occurrence of LAAC device thrombosis in patients with c...
Source: International Journal of Cardiology - November 24, 2015 Category: Cardiology Authors: Ulrike Ketterer, Giuseppe D´ Ancona, Isabel Siegel, Jasmin Ortak, Hueseyin Ince, Stephan Kische Tags: Correspondence Source Type: research
Risk stratification for secondary prevention with ticagrelor and aspirin: A closer look to patient subsets from the PEGASUS-TIMI 54 trial
In the PEGASUS trial, 21,162 patients with a history of myocardial infarction within 1 to 3years earlier were randomized to ticagrelor 90mg twice daily, ticagrelor 60mg twice daily or placebo on a background of low-dose aspirin, and were followed for a median of 33months [1]. Both doses of ticagrelor significantly reduced the primary efficacy endpoint (a composite of cardiovascular death, myocardial infarction, or stroke) but also increased the primary safety endpoint (TIMI major bleeding), compared with placebo [1].
Source: International Journal of Cardiology - August 5, 2015 Category: Cardiology Authors: Davide Capodanno, Piera Capranzano, Sergio Buccheri, Corrado Tamburino Tags: Letter to the Editor Source Type: research
Antiplatelet Therapy in Japanese Patients with Atrial Fibrillation without Oral Anticoagulants: Pooled Analysis of Shinken Database, J-RHYTHM Registry and Fushimi AF Registry
Atrial fibrillation (AF) is the most common cardiac arrhythmia and increases the risk of ischemic stroke. Oral anticoagulants (OAC) are effective for stroke prevention in patients with AF, and recent evidences have revealed the efficacy and safety of non-vitamin K antagonist OAC (NOAC) as well as warfarin. Although aspirin was shown to be inferior to warfarin or apixaban in preventing stroke [1,2], it is still prescribed to many AF patients in clinical practice [3–5]. This may be because physicians perceived it to be a safer and more convenient alternative to OAC.
Source: International Journal of Cardiology - April 22, 2015 Category: Cardiology Authors: Hisashi Ogawa, Masaharu Akao, Shinya Suzuki, Takeshi Yamashita, Ken Okumura, Hirotsugu Atarashi, Hiroshi Inoue Tags: Letter to the Editor Source Type: research
Reply: Health status, geriatric syndromes and prescription of oral anticoagulant therapy in elderly medical in-patients with atrial fibrillation: A prospective observational study
We agree with the content of the letter from Dr Jolobe OMP and, specifically we concur with his conclusion, where he underlines the fragile evidence for aspirin use in the prevention of atrial fibrillation (AF)-related stroke. According to recent European guidelines [1], our study aimed to assess prevalence of and variables associated with under-prescription of currently recommended anticoagulant therapy for AF patients, including vitamin K antagonists (VKAs) and new direct oral anticoagulants (DOAs), but not those associated with use or under-use of aspirin, which is currently not recommended for prevention of AF-related stroke.
Source: International Journal of Cardiology - April 15, 2015 Category: Cardiology Authors: M. Bo, F. Li Puma, M. Badinella Martini, Y. Falcone, M. Iacovino, E. Grisoglio, M. Bonetto, G. Isaia, G. Ciccone, G.C. Isaia, F. Gaita Tags: Letters to the Editor Source Type: research
Acute Myocardial Infarction and Acute Stroke: Between a Rock and a Hard Place
A 53year-old woman developed severe chest pain, breathlessness and palpitations whilst being told some very devastating news. As the symptoms persisted for more than 15minutes, electrocardiography was undertaken in the community confirming an anterolateral STEMI. Following the electrocardiographic findings the patient was loaded orally in the community with aspirin 300mg and clopidogrel 600mg and was urgently transferred via the community activation primary PCI route to our institution for emergency coronary angiography.
Source: International Journal of Cardiology - October 22, 2014 Category: Cardiology Authors: Vassilios Vassiliou, Bushra Rana, Martin Goddard, Denise Braganza Tags: Letter to the editor Source Type: research
Dual antiplatelet therapy versus warfarin anticoagulation in patients undergoing catheter ablation of atrial fibrillation
Radio frequency catheter ablation (RFCA) has become a standard treatment for patients with atrial fibrillation (AF) . Anticoagulation in patients undergoing AF ablation is crucial to minimize the risk of thromboembolic complications. Although warfarin is effective in reducing stroke, its chronic use has many disadvantages including frequent international normalized ratio (INR)/prothrombin, attention to numerous dietary and medication interactions, and risk of serious bleeding including intracranial hemorrhage . Novel oral anticoagulants provide a reasonable alternative; however, they cannot yet be reversed, are expensive, ...
Source: International Journal of Cardiology - March 28, 2014 Category: Cardiology Authors: Zhiyu Ling, Fengpeng Jia, Yanping Xu, Li Su, Zengzhang Liu, Huaan Du, Xiaoyu Yang, Xianbin Lan, Peilin Xiao, Weijie Chen, Jinqi Fan, Suxin Luo, Yuehui Yin, Saman Nazarian Tags: Letters to the Editor Source Type: research
Beyond age, the need for useful parameters to identify heart failure patients in sinus rhythm that can benefit from oral anticoagulation
It is still unclear whether oral anticoagulant or aspirin therapy is superior for patients with heart failure (HF) who are in sinus rhythm. The subanalyses of the warfarin vs. aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial, that have been recently published , were aimed to identify subgroups of patients with reduced left ventricular ejection fraction (LVEF≤35%) in sinus rhythm that may benefit from warfarin or aspirin. They showed that patients under 60years have an improved outcome with warfarin over aspirin concerning the composite outcome of ischemic stroke, intracerebral hemorrhage and overall death, wha...
Source: International Journal of Cardiology - January 23, 2014 Category: Cardiology Authors: Enrico Ammirati, Dacia Dalla Libera, Maria Frigerio Tags: Online Letters to the Editor Source Type: research
Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry
Abstract: Background: Patients with atrial fibrillation (AF) are at increased risk of thromboembolic events. The long-term prognostic implications of AF in patients with atherothrombosis are unknown.Methods: We compared 4-year CV outcomes in patients with and without a history of AF recorded at their baseline visit in the REACH Registry, an international, prospective cohort of patients with established atherosclerotic arterial disease (CAD, CVD, PAD) or at least 3 risk factors (RFO).Results: AF status and 4year follow-up data were available on 44,518 patients. The prevalence of AF at baseline was 10.3% (n=4582). Overall, p...
Source: International Journal of Cardiology - December 9, 2013 Category: Cardiology Authors: Christian T. Ruff, Deepak L. Bhatt, Ph. Gabriel Steg, Bernard J. Gersh, Mark J. Alberts, Elaine B. Hoffman, E. Magnus Ohman, Kim A. Eagle, Gregory Y.H. Lip, Shinya Goto, On Behalf of the REACH Registry Investigators Tags: Original Articles Source Type: research
Apixaban in patients with atrial fibrillation and prior coronary artery disease: Insights from the ARISTOTLE trial
Conclusions: In patients with AF, apixaban more often prevented stroke or systemic embolism and death and caused less bleeding than warfarin, regardless of the presence of prior CAD. Given the common occurrence of AF and CAD and the higher rates of cardiovascular events and death, our results indicate that apixaban may be a better treatment option than warfarin for these high-risk patients.
Source: International Journal of Cardiology - November 4, 2013 Category: Cardiology Authors: Maria Cecilia Bahit, Renato D. Lopes, Daniel M. Wojdyla, Stefan H. Hohnloser, John H. Alexander, Basil S. Lewis, Philip E. Aylward, Freek W.A. Verheugt, Matyas Keltai, Rafael Diaz, Michael Hanna, Christopher B. Granger, Lars Wallentin Tags: Original Articles Source Type: research
